|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
 |
|
|
a Department of Health and Human Services, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA b Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20892, USA
Key Words: VIP • chemotherapeutical • conjugate • breast cancer
Address for correspondence: Dr. T. Moody, NCI Office of the Director, CCR, Bldg. 31, Rm. 4A48, 31 Center Dr. Bethesda, MD 20892. Voice: 301-451-9451; fax: 301-480-4323. e-mail: moodyt{at}mail.nih.gov
VIP receptors were investigated in breast cancer biopsy specimens. Twenty biopsy specimens bound 125I-VIP with high affinity. Also, each of the 20 biopsy specimens had high amounts of VPAC1 receptor mRNA. MCF-7 cells have VPAC1 receptors that bound the VIP chemotherapeutic conjugate, (Ala2,8,9,19,24,25,27 Nle17, Lys28)VIP-L2-camptothecin, with high affinity. VIP chemotherapeutic conjugates may be useful agents to inhibit the growth of breast cancer.
|
 |
 |
